Lignocaine metabolite formation as a measure of pre-transplant liver function

Lancet. 1989 Mar 25;1(8639):640-2. doi: 10.1016/s0140-6736(89)92144-2.

Abstract

A method for rapid assessment of hepatic function in liver donors based on the formation of the lignocaine metabolite monoethylglycinexylidide (MEGX), was used in a prospective study of 69 donor-recipient pairs. The probability of graft survival over 120 days was significantly higher for livers from donors with MEGX test values above 90 micrograms/l than for those from donors with MEGX values of 90 micrograms/l or below. Other liver function tests (bilirubin, prothrombin time, activity of aminotransferases, glutamate dehydrogenase, and cholinesterase, indocyanine green clearance, and galactose elimination capacity) were inefficient at predicting early outcome of transplantation. For a 20-day graft survival, the MEGX test showed prognostic sensitivity of 73% and specificity of 78%. These findings suggest that the MEGX formation test could be valuable for selection of donor organs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Cytochrome P-450 Enzyme System / metabolism
  • Evaluation Studies as Topic
  • Female
  • Graft Survival*
  • Humans
  • Lidocaine / analogs & derivatives*
  • Lidocaine / biosynthesis
  • Lidocaine / blood
  • Lidocaine / metabolism*
  • Liver / metabolism*
  • Liver Function Tests
  • Liver Transplantation
  • Male
  • Middle Aged
  • Preoperative Care
  • Prognosis
  • Prospective Studies
  • Time Factors

Substances

  • Cytochrome P-450 Enzyme System
  • Lidocaine
  • monoethylglycinexylidide